Mick van Eijs

PHD Candidate - Medical

Strategic program(s):

Biography

Current position:

PhD candidate onco-immunology, UNICIT study: UNICIT - UMC Utrecht

More info on our research

Education:

2016-2020 Medicine (MSc), Utrecht University

2017-2018 Health Economics, Policy and Law (MSc), Erasmus University Rotterdam

2013-2016 Medicine (BSc), Utrecht University

Strategic program(s):

Contact

meijs2@umcutrecht.nl

Pure profile

Recent publications

All publications

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma Rik J. Verheijden, Femke H. Burgers, Josephine C. Janssen, Anouk E. Putker, Sophie P.G.R. Veenstra, Geke A.P. Hospers, Maureen J.B. Aarts, Karel W. Hehenkamp, Veerle L.E. Doornebosch, Marthe Verhaert, Franchette W.P.J. van den Berkmortel, Katerina Chatzidionysiou, Arturo Llobell, Milton Barros, Alexandre T.J. Maria, Akari Takeji, José Salvador García Morillo, Merav Lidar, Mick J.M. van Eijs, Christian U. Blank, Sandrine Aspeslagh, Djura Piersma, Ellen Kapiteijn, Mariette Labots, Marye J. Boers-Sonderen, Astrid A.M. van der Veldt, John B.A.G. Haanen, Anne M. May, Karijn P.M. Suijkerbuijk
European Journal of Cancer, 2024, vol. 207

Clinical and translational attributes of immune-related adverse events Karijn P M Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, Alexander M M Eggermont
Nature Cancer, 2024, vol. 5, p.557-571

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis Mick J.M. van Eijs, José J.M. ter Linde, Matthijs J.D. Baars, Mojtaba Amini, Miangela M. Laclé, Eelco C. Brand, Eveline M. Delemarre, Julia Drylewicz, Stefan Nierkens, Rik J. Verheijden, Bas Oldenburg, Yvonne Vercoulen, Karijn P.M. Suijkerbuijk, Femke van Wijk
iScience, 2023, vol. 26

Immunosuppression for immune-related adverse events during checkpoint inhibition Rik J Verheijden, Mick J M van Eijs, Anne M May, Femke van Wijk, Karijn P M Suijkerbuijk
NPJ precision oncology, 2023, vol. 7

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies Olivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, Rozemarijn S van Rijn, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Marye J Boers-Sonderen, Mick J M van Eijs, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Melissa de Meza, Djura Piersma, Marion Stevense-den Boer, Astrid A M van der Veldt, Gerard Vreugdenhil, Michel W J M Wouters, Karijn P M Suijkerbuijk, Willeke A M Blokx
European Journal of Cancer, 2023, vol. 186, p.27-37

Physical activity and checkpoint inhibition Rik J Verheijden, Anna Cabané Ballester, Karel C Smit, Mick J M van Eijs, Cheryl P Bruijnen, Anne S R van Lindert, Karijn P M Suijkerbuijk, Anne M May
Journal of the National Cancer Institute, 2023, vol. 116, p.573-579